Simris Biologics identify novel compounds from cyanobacteria and microalgae, developing patented technology platforms. They are pioneering next-generation cancer therapeutics using cyanobacteria toxins. Specifically, they've developed microcystins as Antibody Drug Conjugates (ADC), a cutting-edge cancer treatment. Currently in the preclinical stage, which lasts 2 to 3 years, Simris Biologics is advancing towards innovative and effective cancer therapies.
